EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...
Controlling a computer with your mind was once pure science fiction, but it's now plausible thanks to brain-computer ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
TOKYO, Nov 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be ...
Dr. Kota Takayama was also part of the research team that investigated challenges for sign language interpretation in ...
In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.
The CHMP recommends approval of lecanemab for the treatment of mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease, in adult patients who are heterozygotes (carry one copy) ...
The European Union's drugs regulator on Thursday recommended approval for Eisai and Biogen's Leqembi in some patients with ...
Members of the Ontario Nurses' Association (ONA) staged a hospital understaffing graveyard today outside the Ontario Hospital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback